Quantitative Sandwich ELISA for Chitinase-3-like Protein 1 — Inflammation & Cancer Biomarker
The YKL-40 / CHI3L1 ELISA Antibody Pair enables quantitative measurement of Chitinase-3-like Protein 1 (CHI3L1) — also known as YKL-40 and HC-gp39 — a secreted glycoprotein that serves as a clinically validated biomarker across multiple disease areas including cancer, asthma, rheumatoid arthritis, and liver fibrosis.
Validated in a sandwich ELISA format with six calibrators spanning 0–600 ng/mL, the antibody pair delivers within-run CV ≤7.1% and has been benchmarked against a commercial ELISA kit across 46 clinical samples. The pair is suitable for OEM ELISA kit development and FIA lateral flow adaptation.
Antibody pair performance validated across calibration, precision, linearity, and clinical sample correlation.
Six-calibrator curve spanning 0–600 ng/mL covers the physiological range (normal: ~40 ng/mL) through disease-associated elevations seen in severe inflammation, cancer, and organ fibrosis.
Within-run CV ≤7.1% at low control (~75 ng/mL) and ≤6.8% at high control (~300 ng/mL) across 10 replicates — meeting IVD precision acceptance criteria.
Dilution linearity CV ≤4.8% across six concentration levels demonstrates proportional dose-response and accurate back-calculation from the calibration curve.
Strong concordance demonstrated across 46 clinical serum samples (range ~15–320 ng/mL) compared to a commercial ELISA benchmark — confirming clinical utility.
CHI3L1/YKL-40 is elevated in cancer, rheumatoid arthritis, asthma, IBD, and liver fibrosis. A single antibody pair enables research across multiple disease indications.
Capture and detection antibody pair validated for sandwich ELISA. Also compatible with FIA lateral flow format for point-of-care CHI3L1 quantification.
All data generated using Sekbio anti-CHI3L1 monoclonal antibody pair in sandwich ELISA format (OD450).
Six-point calibration spanning 0–600 ng/mL demonstrates a robust sigmoidal dose-response with OD450 readings increasing proportionally from 0.012 (blank) to 2.390 at 600 ng/mL.
| Calibrator | Conc. (ng/mL) | OD Run 1 | OD Run 2 | Avg. OD |
|---|---|---|---|---|
| Cal 1 | 0 | 0.014 | 0.010 | 0.012 |
| Cal 2 | 37.5 | 0.327 | 0.318 | 0.323 |
| Cal 3 | 75 | 0.609 | 0.588 | 0.599 |
| Cal 4 | 150 | 1.057 | 1.029 | 1.043 |
| Cal 5 | 300 | 1.746 | 1.627 | 1.687 |
| Cal 6 | 600 | 2.406 | 2.373 | 2.390 |
| OD measured at 450 nm. Duplicate readings per calibrator level. | ||||
Two control levels (R1 ≈75 ng/mL; R2 ≈300 ng/mL) measured in 10 replicates demonstrate CV values well within the IVD acceptance criterion of ≤10%.
| Control | Approx. Conc. (ng/mL) | Replicates (n) | Avg. OD | OD CV (%) | Avg. Conc. (ng/mL) | Conc. CV (%) |
|---|---|---|---|---|---|---|
| R1 | ~75 | 10 | 0.597 | 6.1% | 75.1 | 7.1% |
| R2 | ~300 | 10 | 1.669 | 4.0% | 296.4 | 6.8% |
| OD CV = variability of raw absorbance; Conc. CV = variability of back-calculated concentration. | ||||||
Serial dilution of a high-concentration sample across six levels confirms proportional dose-response with CV ≤4.8%, validating the full analytical range.
| Theoretical Conc. (ng/mL) | Replicate 1 | Replicate 2 | Replicate 3 | Avg. (ng/mL) | CV (%) |
|---|---|---|---|---|---|
| 32.8 | 32.7 | 31.3 | 34.4 | 32.8 | 4.8% |
| 139.4 | 136.4 | 141.0 | 149.1 | 142.2 | 4.5% |
| 245.9 | 246.6 | 245.1 | 253.8 | 248.5 | 1.9% |
| 352.5 | 338.9 | 351.0 | 375.0 | 355.0 | 5.2% |
| 459.0 | 449.4 | 461.8 | 445.1 | 452.1 | 1.9% |
| 565.6 | 570.6 | 558.9 | 567.3 | 565.6 | 1.1% |
| Serial dilutions of a high-pool sample. CV ≤4.8% across all levels confirms linear response. | |||||
Forty-six clinical serum samples (range ~15–320 ng/mL) were measured in parallel using the Sekbio CHI3L1 ELISA and a commercial benchmark kit. Results demonstrate strong proportional agreement across the clinical range.
The CHI3L1 antibody pair supports research and diagnostic applications across oncology, pulmonology, and rheumatology.
CHI3L1 elevation is associated with breast, lung, colorectal, and ovarian cancers. Quantitative ELISA enables prognosis studies, treatment response monitoring, and tumor biology research.
Serum YKL-40 correlates with asthma severity and lung function. The assay supports clinical research on airway inflammation, eosinophilic subtyping, and biologic therapy stratification.
Elevated CHI3L1 in rheumatoid arthritis, IBD, and liver cirrhosis enables disease activity monitoring and therapeutic response assessment in longitudinal cohort studies.
Capture and detection antibody pair available as OEM raw material for licensed ELISA kit manufacturers. Compatible with standard 96-well microplate sandwich format.
Request the full technical datasheet, antibody pair specifications, or discuss OEM kit development and bulk supply with our team.